We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Facebook, Novo Nordisk, SAP, Royal Dutch Shell and American Express
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 28, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Facebook, Inc. , Novo Nordisk A/S (NVO - Free Report) , SAP SE (SAP - Free Report) , Royal Dutch Shell plc and American Express Company (AXP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Facebook, Novo Nordisk and SAP
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Facebook, Novo Nordisk and SAP SE. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Facebook shares have outperformed the S&P 500 over the past year (+26.3% vs. +19.7%) on the back of steady user growth across all regions, particularly Asia Pacific. Increased engagement for its products like Instagram, WhatsApp, Messenger and Facebook Watch is a major growth driver.
However, Facebook expects user-base growth to be flat or slightly down in the United States and Canada in the fourth quarter of 2020, sequentially. Ad-revenue growth on a year-over-year basis is expected to be better than the third quarter’s growth rate, driven by continued strong advertiser demand during the holiday season.
Strong demand for Oculus 2 is expected to boost other revenues. However, changes made by Apple and Google in their mobile operating systems and browser platforms have limited Facebook’s ability to track user-activity trend, which is a headwind.
Shares of Novo Nordisk have gained +6% in the last six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +7.9%. The Zacks analyst believes that Tresiba, Victoza, Ozempic, Xultophy and Saxenda have been maintaining the momentum for the company. Label expansion of existing drugs will further boost sales for the company.
Novo Nordisk missed on sales but beat earnings estimates in the third quarter. Ozempic is off to a solid start and the launch of Rybelsus looks good. The label of Ozempic was further expanded by the Food and Drug Administration (FDA) to include a cardiovascular indication. Novo Nordisk has one of the broadest diabetes portfolios in the industry.
However, lower realized prices in the Unites States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will affect sales. Moreover, the impact of COVID-19 will adversely affect the performance in the upcoming quarters.
SAP shares have gained +21% over the past three months against the Zacks Computer Software industry’s rise of +13.8%. The Zacks analyst believes that SAP is benefiting from robust uptake of S/4HANA, Fieldglass, and SuccessFactors Employee Central solutions.
Further, SAP's alliances with IBM, Microsoft, Accenture and Verizon favor business prospects. The company is poised to gain from solid contribution from Sapphire Ventures. Further, high demand for e-commerce, digital supply chain, Qualtrics and cloud platform solutions, bodes well.
However, a rise in investments to enhance cloud-based offerings are likely to weigh on margins in the near term. Soft uptake of software licenses and support offerings remains a headwind. Recently, the company reported preliminary results for Q4 wherein total revenues (non-IFRS basis) declined on a year-over-year basis.
Other noteworthy reports we are featuring today include Royal Dutch Shell and American Express.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Facebook, Novo Nordisk, SAP, Royal Dutch Shell and American Express
For Immediate Release
Chicago, IL – January 28, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Facebook, Inc. , Novo Nordisk A/S (NVO - Free Report) , SAP SE (SAP - Free Report) , Royal Dutch Shell plc and American Express Company (AXP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Facebook, Novo Nordisk and SAP
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Facebook, Novo Nordisk and SAP SE. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Facebook shares have outperformed the S&P 500 over the past year (+26.3% vs. +19.7%) on the back of steady user growth across all regions, particularly Asia Pacific. Increased engagement for its products like Instagram, WhatsApp, Messenger and Facebook Watch is a major growth driver.
However, Facebook expects user-base growth to be flat or slightly down in the United States and Canada in the fourth quarter of 2020, sequentially. Ad-revenue growth on a year-over-year basis is expected to be better than the third quarter’s growth rate, driven by continued strong advertiser demand during the holiday season.
Strong demand for Oculus 2 is expected to boost other revenues. However, changes made by Apple and Google in their mobile operating systems and browser platforms have limited Facebook’s ability to track user-activity trend, which is a headwind.
(You can read the full research report on Facebook here >>>)
Shares of Novo Nordisk have gained +6% in the last six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +7.9%. The Zacks analyst believes that Tresiba, Victoza, Ozempic, Xultophy and Saxenda have been maintaining the momentum for the company. Label expansion of existing drugs will further boost sales for the company.
Novo Nordisk missed on sales but beat earnings estimates in the third quarter. Ozempic is off to a solid start and the launch of Rybelsus looks good. The label of Ozempic was further expanded by the Food and Drug Administration (FDA) to include a cardiovascular indication. Novo Nordisk has one of the broadest diabetes portfolios in the industry.
However, lower realized prices in the Unites States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will affect sales. Moreover, the impact of COVID-19 will adversely affect the performance in the upcoming quarters.
(You can read the full research report on Novo Nordisk here >>>)
SAP shares have gained +21% over the past three months against the Zacks Computer Software industry’s rise of +13.8%. The Zacks analyst believes that SAP is benefiting from robust uptake of S/4HANA, Fieldglass, and SuccessFactors Employee Central solutions.
Further, SAP's alliances with IBM, Microsoft, Accenture and Verizon favor business prospects. The company is poised to gain from solid contribution from Sapphire Ventures. Further, high demand for e-commerce, digital supply chain, Qualtrics and cloud platform solutions, bodes well.
However, a rise in investments to enhance cloud-based offerings are likely to weigh on margins in the near term. Soft uptake of software licenses and support offerings remains a headwind. Recently, the company reported preliminary results for Q4 wherein total revenues (non-IFRS basis) declined on a year-over-year basis.
(You can read the full research report on SAP here >>>)
Other noteworthy reports we are featuring today include Royal Dutch Shell and American Express.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
AccessZacks Top 10 Stocks for 2021 today >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.